Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

(2020) Deborah Nejman et al.   SCIENCE

Chemotherapy for pancreatic cancer

(2019) Christoph Springfeld et al.   PRESSE MEDICALE

Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

(2019) Erick Riquelme et al.   CELL

Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response

(2018) Vrishketan Sethi et al.   GASTROENTEROLOGY

Therapeutic developments in pancreatic cancer: current and future perspectives

(2018) John P. Neoptolemos et al.   Nature Reviews Gastroenterology & Hepatology

Management and supportive treatment of frail patients with metastatic pancreatic cancer

(2018) Teresa Macarulla et al.   Journal of Geriatric Oncology

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

(2017) Leore T. Geller et al.   SCIENCE

Response assessment in pancreatic ductal adenocarcinoma: role of imaging

(2017) Vinit Baliyan et al.   Abdominal Radiology

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma

(2015) Steffen Ormanns et al.   BRITISH JOURNAL OF CANCER

Local bacteria affect the efficacy of chemotherapeutic drugs

(2015) Panos Lehouritis et al.   Scientific Reports

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

(2012) Volker Heinemann et al.   GUT

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE